Short answer
Design Therapeutics, Inc. (DSGN) filed an 8-K current report with the SEC on April 28, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Q1 2026 financial results announced for the three months ended March 31, 2026.
Design Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q1 2026 financial results announced for the three months ended March 31, 2026
- Detailed results and management commentary available in Exhibit 99.1
- Investor focus: cash position, operating expenses, and development funding implications
Item 7.01 · Regulation FD Disclosure
- Updated corporate presentation signals new investor-facing messaging or business updates as of April 28, 2026
- Presentation available on Design Therapeutics’ investor website with recorded narrative
- Exhibit 99.2 contains the substantive materials investors should review
- Disclosure furnished under Regulation FD, limiting its status as a filed Exchange Act disclosure
Item EX-99.1 · Exhibit EX-99.1
- Q1 2026 net loss $17.6M, or $0.29 per share, versus $17.7M and $0.31 in Q1 2025
- Cash, equivalents and securities $222.8M, with expected funding into 2029, reducing near-term financing risk
- RESTORE-FA continues dosing DT-216P2, with endogenous frataxin data anticipated in the second half of 2026
- DT-168 FECD biomarker data expected in the second half of 2026, creating a second clinical catalyst
- DT-818 DM1 dosing expected in the first half of 2026, with results anticipated in 2027
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Design Therapeutics, Inc. 8-K filings
Get the next DSGN 8-K as it lands
Follow DSGN for push alerts, or ask the research agent what this filing means.